CCL2 Predicts Survival in Patients with Inoperable Hepatocellular Carcinoma Undergoing Selective Internal Radiotherapy.
Florian HaagSeverin GylstorffJasmin BujokMaciej PechBorna ReljaPublished in: Cancers (2024)
CCL2 may serve as a potential marker for patient survival after SIRT. The prediction of which HCC patients are likely to benefit from SIRT may be helpful in guiding therapeutic management.
Keyphrases
- end stage renal disease
- ejection fraction
- oxidative stress
- newly diagnosed
- locally advanced
- chronic kidney disease
- radiation therapy
- liver fibrosis
- prognostic factors
- peritoneal dialysis
- liver injury
- ischemia reperfusion injury
- case report
- squamous cell carcinoma
- patient reported outcomes
- human health
- free survival
- rectal cancer